Polo GGB will be present at the 2024 SIGU National Congress, the main event for the scientific community in the field of human genetics. This meeting, scheduled for October 2-4 in Padua, will provide an opportunity to present our experience and innovative services in genomics, with a particular focus on Next Generation Sequencing (NGS) technologies and personalized diagnostic pathways.
The importance of NGS services
We are pioneers in the development of advanced sequencing services, crucial for high-resolution genetic analysis. These tools are fundamental for the diagnosis and management of hereditary, oncological, and rare diseases. Our cutting-edge platforms and highly qualified staff allow us to deliver rapid and accurate results, improving clinical intervention.
Our services include prenatal genetic testing, oncogenetics, and genomic solutions for personalized medicine, ensuring increasingly targeted and effective diagnostics.
SSN Accreditation: A milestone achieved
The accreditation with the National Health System (SSN) obtained from the Tuscany Region is a significant achievement, making our NGS services accessible to a larger number of patients. This milestone certifies our compliance with the highest quality standards, benefiting both public and private healthcare facilities.
Congress Themes
During the SIGU 2024 Congress, key topics such as prenatal genetics, oncogenetics, reproductive genetics, and pharmacogenomics will be addressed. Our participation will allow us to share expertise and successes in improving diagnostic pathways.
Commitment to innovation and research
Our involvement in scientific events like SIGU is essential for spreading technological innovation in sequencing services. We are dedicated to developing advanced diagnostic solutions that improve the quality of care pathways, offering physicians and patients access to cutting-edge technologies for early diagnosis and the management of genetic disorders.
Towards the future of medical genetics in Italy
Participation in SIGU 2024 marks a crucial step for the Polo GGB in strengthening our role in the landscape of Italian medical genetics. We will continue to invest in technologies and research, actively contributing to the growth of the national healthcare system through an innovative and precise approach.
